Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02538341 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 617
- Enrollment target
NCT02538341 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 617 participants.
The verdict
NCT02538341, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 617 participants
- Enrollment target
Study Summary
The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor necrosis factor (TNF) therapy and who have not previously received the vaccine.
Interventions
- DRUG Placebo
- BIOLOGICAL Herpes Zoster (HZ) Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 617 participants |
| Start Date | 2016-05 |
| Est. Completion | 2020-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02538341
The ClinicalTrials.gov registry entry for NCT02538341 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 617 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02538341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02538341 about?
NCT02538341 is a clinical study titled "Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)". The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor necrosis factor (TNF) therapy and who have not previously received the ...
What is the current status of trial NCT02538341?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 617 participants. The study started on 2016-05. Estimated completion is 2020-12.
What interventions are being tested in trial NCT02538341?
The interventions under investigation include: Placebo (DRUG), Herpes Zoster (HZ) Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02538341?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.